Merck & Co., Inc. (MRK)
| Market Cap | 226.40B |
| Revenue (ttm) | 64.17B |
| Net Income (ttm) | 17.12B |
| Shares Out | 2.53B |
| EPS (ttm) | 6.74 |
| PE Ratio | 13.29 |
| Forward PE | 9.95 |
| Dividend | $3.24 (3.62%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 15,638,443 |
| Open | 88.00 |
| Previous Close | 87.68 |
| Day's Range | 87.01 - 89.52 |
| 52-Week Range | 81.04 - 134.63 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 120.31 (+34.43%) |
| Earnings Date | Feb 4, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $120.31, which is an increase of 34.43% from the latest price.
News
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Merck & Co (“Merck” or th...
I'm Buying Discounted Dividend Icons Up To 6% Yield
Great dividend stocks should offer a mix of durability, solid income generation, and growth prospects. In this article, I highlight 2 such names, both of which are trading at discounted valuations com...
Merck & Co (MRK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Merck & Co (“Merck” or the “Company”) (NYSE: MRK) investors concerning the Company's possible vio...
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Merck & Co (“Merck” or the “Company”) (NYSE: MRK) on behalf of investors concerning the Company's possible ...
10 Ideal 'Safer' January Dividend Buys, Out Of 40 Choices From Readers
Before January 31, 2025, my REaders mentioned 40 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about the ReFa/Ro. ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options If you suff...
Calls of the Day: Gilead Sciences and Merck
The Investment Committee debate the Calls of the Day in two biotech names.
Exclusive: Merck vaccine case linked to HHS Secretary Kennedy delayed, company says
Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus vaccine in a case with ties to U.S. Department of Health and Human Services...
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG Receives First European Commission Approval for Two Indications.
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Merck & Co., Inc. (MRK)
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey...
Rosen Law Firm Urges Merck & Co., Inc. (NYSE: MRK) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Merck & Co., Inc. (NYSE: MRK) b...
US pharma giant Merck backs healthcare marketplace HD in Southeast Asia
Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare industry. Just last month, AWS and General Catalyst announced their partnership t...
Merck Employees Federal Credit Union Partners with Carefull to Combat Rising Elder Fraud and Scam Threats
NEW YORK--(BUSINESS WIRE)--With Carefull, MEFCU equips members with cutting-edge financial security tools amid rising fraud threats.
One 'Safer' Buy In 10 February Dogs Of The Dow
Verizon is the only Dow Dog meeting the ideal of dividends from $1K invested exceeding single share price, supported by adequate free cash flow. Analysts project net gains of 15.23% to 33.94% for the ...
Top 3 Health Care Stocks You'll Regret Missing This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial e...
Merck: Don't Fight The Tape, How Low Can It Go?
Despite Merck & Co., Inc.'s strong fundamentals and promising pipeline, current negative sentiment suggests avoiding the stock until it stabilizes and shows signs of recovery. Merck's stock is underva...
Should You Pick MRK Stock At $90?
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per share, c...
Final Trade: SNAP, PYPL, SPYV, MRK
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Stock Market Today: Earnings Speak Louder Than Tariffs
Recent market reaction to Trump administration policy announcements has been "entirely normal."
Guggenheim Securities' Vamil Divan breaks down Merck's stock drop
Vamil Divan, Guggenheim Securities biopharmaceutical analyst, joins 'Power Lunch' to discuss Merck's troubles in China.
Merck: Ideal Case Of Why I Love Option Collars (Upgrade To Buy)
Merck's current high-risk profile led me to initially rate it a strong sell, but recent technical indicators suggested a potential bottom near $100. I've upgraded MRK to a buy, using a "Dog Collar" st...
Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
Healthcare costs are rising, with PwC projecting the highest commercial healthcare spending growth in 13 years, impacting consumers and insurance companies negatively. Healthcare stocks, including Mer...
Merck & Co., Inc. (MRK) Q4 2024 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK) Q4 2024 Results Conference Call February 4, 2025 9:00 AM ET Company Participants Peter Dannenbaum - Senior Vice President, Investor Relations Rob Davis - Chairman and Chi...
PYPL & MRK Sell Off Despite Strong Earnings, EL to Cut 7,000 Jobs
While companies like Palantir (PLTR) and Spotify (SPOT) rally big on earnings, PayPal (PYPL) and Merck (MRK) sold off despite their big beats. Merck, however, shared soft guidance that shook investors...